Virtual platform aims to cut HIV comorbidities
NCT ID NCT06580184
First seen Feb 21, 2026 · Last updated Jun 23, 2026 · Updated 13 times
Summary
This study tests a virtual platform called LEARN 2 that provides tailored education to help men living with HIV prevent related health problems like heart disease and metabolic issues. Participants will use the platform weekly, attend live health educator sessions, and track their daily behaviors. Researchers will compare their quality of life and risk factors to a waitlist group to see if the program makes a difference.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Yale University
Orange, Connecticut, 06477, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
LEARN 2 Platform (behavioral intervention)
What this could lead to
If it works, this could provide an effective way to reduce the risk of serious health problems like heart disease in people living with HIV.
What could go wrong
This is a small, early-stage trial with no drug involved, so any benefits may be modest. The results may not apply to all people with HIV.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.